Who needs another PD-1 checkpoint inhibitor?
There are 6 on the US market, plus a bunch coming in from China, with GlaxoSmithKline among the major players — Novartis, etc — looking to craft their own R&D strategy that can carve into the field. Merck’s dominant Keytruda is now officially in more than 1,000 clinical trials, including a string of combo studies.
So how does a relatively small biotech like Arcus Biosciences compete with a PD-1 licensed from China’s WuXi in a deal fronted with just $18.5 million?
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription